Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourLeaning Bearish
15 minLeaning Bearish
5 minSymmetric Triangle
Daily trend turns down below $15.47
Key levels
Resistance$21.69
Support$20.77
Support$19.52
Latest news & SEC filings
DealBausch Health reviews strategic options for Bausch + Lomb
NewsBausch + Lomb Executive Frederick Munsch Offloads Stock
SEC FilingBausch & Lomb Corp filed an insider trading report (Form 4)
AnalystHC Wainwright cuts Bausch + Lomb rating to Neutral
AnalystAnalyst cuts Bausch & Lomb rating to Neutral, target now $22
All BLCO news →Bausch + Lomb is an eye health company that develops, manufactures, and markets products for vision care. Its offerings span contact lenses, lens care solutions, surgical devices and instruments, and prescription eye medications and supplements. The company serves eye care professionals, hospitals, retailers, and consumers worldwide, operating across roughly 100 countries.
Based on the company's 10-K filed Feb 18, 2026.
NYSE · Healthcare
SEPT Low Target
$16.00
SEPT Mid Target
$22.00
SEPT High Target
$24.00
Analyst Consensus
$22.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BLCO.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$25.00
14
Moat Score
NONE
3/9
Piotroski Score
1.0
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| ROBERTSON RUSSEL C | director | Buy | 1,256 | $26K | Oct 29, 2026 |
| Paulson John | director | Buy | 1,125 | $23K | Oct 29, 2026 |
| VON ESCHENBACH ANDREW C. | director | Buy | 15,842 | $250K | May 26, 2026 |
| Ross Thomas W. Sr. | director | Buy | 15,842 | $250K | May 26, 2026 |
| ROBERTSON RUSSEL C | director | Buy | 15,842 | $250K | May 26, 2026 |
| Paulson John | director | Buy | 15,842 | $250K | May 26, 2026 |
| Ling Karen | director | Buy | 15,842 | $250K | May 26, 2026 |
| KAVANAGH SARAH B | director | Buy | 15,842 | $250K | May 26, 2026 |
| COLLIS STEVEN H | director | Buy | 15,842 | $250K | May 26, 2026 |
| Bernier Nathalie D. | director | Buy | 15,842 | $250K | May 26, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
6.5%
3yr Revenue CAGR
10.6%
EPS Growth YoY
-13.33%
FCF Growth YoY
-11.9%
Revenue Trend
STABLE
SEPT Investing tracks real-time dark pool institutional trades for BLCO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:30:04 | $20.84 | 2,132 | $$44K | SELL |
| 14:30:03 | $20.82 | 10,000 | $$208K | SELL |
| 14:30:02 | $21.16 | 1,262 | $$27K | SELL |
| 14:30:01 | $21.25 | 1,800 | $$38K | BUY |
| 14:30:01 | $21.25 | 2,500 | $$53K | BUY |
5 dark pool trades shown · $$371K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Bausch & Lomb Corp (BLCO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Bausch & Lomb Corp (BLCO) is at $21.30, down 0.12% (-$0.02) at the Nov 12, 2026 close.
Latest BLCO news — Nov 4, 2026: Bausch Health reviews strategic options for Bausch + Lomb · Nov 2, 2026: Bausch + Lomb Executive Frederick Munsch Offloads Stock
The average analyst price target for BLCO is $22.00, ranging from $16 to $24, based on 8 analysts. Latest: HC Wainwright & Co. downgrade on Nov 2, 2026.
Analyst ratings for BLCO: 0 Buy, 10 Hold, 0 Sell — consensus Hold.
BLCO last reported on Oct 28, 2026: EPS $0.34 vs $0.21 expected — a beat of 58.5%.
BLCO does not currently pay a dividend.
Bausch & Lomb Corp reported $5.0B of debt and $513M of cash (Sep 30, 2026).
Support: $20.77, $19.52, $18.46. Resistance: $21.69.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 4, 2026: Bausch Health reviews strategic options for Bausch + Lomb · Nov 2, 2026: Bausch + Lomb Executive Frederick Munsch Offloads Stock · Nov 2, 2026: Bausch & Lomb Corp filed an insider trading report (Form 4)